Reference : Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: ...
Scientific journals : Article
Human health sciences : Gastroenterology & hepatology
Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort
Schnitzler, F. [ > > ]
Fidder, H. [> > > >]
Ferrante, M. [ > > ]
Noman, M. [> > > >]
Arijs, I. [> > > >]
Van Assche, G. [> > > >]
Hoffman, I. [> > > >]
Van Steen, Kristel mailto [Université de Liège - ULiège > Dép. d'électric., électron. et informat. (Inst.Montefiore) > Bioinformatique >]
Vermeire, S. [> > > >]
Rutgeerts, P. [> > > >]
[en] Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal/adverse effects/*therapeutic use ; Crohn Disease/*drug therapy/surgery ; Drug Administration Schedule ; Drug Therapy, Combination ; Drug Tolerance ; Female ; Follow-Up Studies ; Gastrointestinal Agents/adverse effects/*therapeutic use ; Glucocorticoids/administration & dosage/therapeutic use ; Hospitalization/statistics & numerical data ; Humans ; Immunosuppressive Agents/adverse effects/therapeutic use ; Male ; Middle Aged ; Prognosis ; Prospective Studies ; Treatment Outcome ; Tumor Necrosis Factor-alpha/antagonists & inhibitors
[en] BACKGROUND AND AIMS: This observational study assessed the long-term clinical benefit of infliximab (IFX) in 614 consecutive patients with Crohn's disease (CD) from a single centre during a median follow-up of 55 months (interquartile range (IQR) 27-83). METHODS: The primary analysis looked at the proportion of patients with initial response to IFX who had sustained clinical benefit at the end of follow-up. The long-term effects of IFX on the course of CD as reflected by the rate of surgery and hospitalisations and need for corticosteroids were also analysed. RESULTS: 10.9% of patients were primary non-responders to IFX. Sustained benefit was observed in 347 of the 547 patients (63.4%) receiving long-term treatment. In 68.3% of these, treatment with IFX was ongoing and in 31.7% IFX was stopped, with the patient being in remission. Seventy patients (12.8%) had to stop IFX due to side effects and 118 (21.6%) due to loss of response. Although the yearly drop-out rates of IFX in patients with episodic (10.7%) and scheduled treatment (7.1%) were similar, the need for hospitalisations and surgery decreased less in the episodic than in the scheduled group. Steroid discontinuation also occurred in a higher proportion of patients in the scheduled group than in the episodic group. CONCLUSIONS: In this large real-life cohort of patients with CD, long-term treatment with IFX was very efficacious to maintain improvement during a median follow-up of almost 5 years and changed disease outcome by decreasing the rate of hospitalisations and surgery.

File(s) associated to this reference

Fulltext file(s):

Restricted access
Schnitzler2009_gut.pdfPublisher postprint646.21 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.